摘要
目的:评价西黄丸联合吉西他滨对中晚期胰腺癌患者的治疗价值。方法:将我院32例中晚期胰腺癌患者随机分为A组与B组,分别进行吉西他滨化学治疗和中药西黄丸+化疗的中西医结合疗法,观察各组实体瘤、血清CA19-9、体力状况、临床症状及毒副反应等方面的变化。结果:B(西黄丸联合吉西他滨)组临床受益率(CR+PR+NC)优于A(吉西他滨)组,两组在降低血清CA19-9水平、卡氏评分提高、症状改善率、白细胞减少方面均有显著性差异(P<0.05)。结论:西黄丸联合吉西他滨治疗中晚期胰腺癌具有延缓实体瘤增长,降低CA19-9,改善临床症状,提高患者生活质量,减轻化疗引起白细胞减少的毒副反应,对中晚期胰腺癌患者显示出良好的临床受益反应。
AIM： To evaluate treatment value of Xihuang Pill combined gemcitabine for advanced pancreatic cancer patients. METHODS： Thirty-two patients with advanced pancreatic cancer were randomly divided into A group and B group, treated with gemcitabine chemotherapy and traditional Chinese medicine Xihuang Pill ＋ chemotherapy treatment, respectively. The changes of the solid tumor, serum CA19-9, physical status, clinical symptoms and toxicity were observed. RESULTS： B group （Xihuang Pill combined with gemcitabine） clinical return ratio （ CR ＋ PR ＋ NC） was better than A group （gemcitabine）. There was significant difference between two groups in the reduction of serum CA19-9 level, Karnofsky score increased, the rate of symptom improvement, Leukopenia reduction （ P 〈 0.05 ）. CONCLUSION ： Integrating Xihuang Pill and gemcitabine in the treatment of advanced pancreatic cancer： delaying of tumor growth, reducing of CA19-9 level, improving of the clinical symptoms and life quality of patients, reducing of neutropenia in patients （ chemotherapy-induced toxicity） , shows good clinical benefit response.
出处
《中成药》
CAS
CSCD
北大核心
2010年第1期13-15,共3页
Chinese Traditional Patent Medicine
关键词
胰腺癌
西黄丸
吉西他滨
中西医结合治疗
pancreatic carcinoma
Xihuang Pill
gemcitabine
combining treatment with traditional Chinese medicine and western medicine
